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SpOBJECTIVES This study compared diagnostic accuracy of conventional troponin/traditional coronary artery disease
(CAD) assessment and highly sensitive troponin (hsTn) I/advanced CAD assessment for acute coronary syndrome (ACS)
during the index hospitalization.
BACKGROUND hsTnI and advanced assessment of CAD using coronary computed tomography angiography (CTA) are
promising candidates to improve the accuracy of emergency department evaluation of patients with suspected ACS.
METHODS We performed an observational cohort study in patients with suspected ACS enrolled in the ROMICAT II (Rule
Out Myocardial Infarction/Ischemia using Computer Assisted Tomography) trial and randomized to coronary CTA who
also had hsTnI measurement at the time of the emergency department presentation. We assessed coronary CTA for
traditional (no CAD, nonobstructive CAD, $50% stenosis) and advanced features of CAD ($50% stenosis, high-risk
plaque features: positive remodeling, low <30-Hounsﬁeld units plaque, napkin-ring sign, spotty calcium).
RESULTS Of 160 patients (mean age: 53  8 years, 40% women) 10.6% were diagnosed with ACS. The ACS rate in
patients with hsTnI below the limit of detection (n ¼ 9, 5.6%), intermediate (n ¼ 139, 86.9%), and above the 99th
percentile (n ¼ 12, 7.5%) was 0%, 8.6%, and 58.3%, respectively. Absence of $50% stenosis and high-risk plaque ruled
out ACS in patients with intermediate hsTnI (n ¼ 87, 54.4%; ACS rate 0%), whereas patients with both $50% stenosis
and high-risk plaque were at high risk (n ¼ 13, 8.1%; ACS rate 69.2%) and patients with either$50% stenosis or high-risk
plaque were at intermediate risk for ACS (n ¼ 39, 24.4%; ACS rate 7.7%). hsTnI/advanced coronary CTA assessment
signiﬁcantly improved the diagnostic accuracy for ACS as compared to conventional troponin/traditional coronary CTA
(area under the curve 0.84, 95% conﬁdence interval [CI]: 0.80 to .88 vs. 0.74, 95% CI: 0.70 to 0.78; p < 0.001).
CONCLUSIONS hsTnI at the time of presentation followed by early advanced coronary CTA assessment improves the
risk stratiﬁcation and diagnostic accuracy for ACS as compared to conventional troponin and traditional coronary CTA
assessment. (Multicenter Study to Rule Out Myocardial Infarction/Ischemia by Cardiac Computed Tomography
[ROMICAT-II]; NCT01084239) (J Am Coll Cardiol Img 2015;8:1272–81) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
AUC = area under the receiver
operating characteristics curve
CAD = coronary artery disease
CI = conﬁdence interval
CTA = computed tomography
angiography
ED = emergency department
hsTn = highly sensitive
troponin
HU = Hounsﬁeld units
LOD = limit of detection
NPV = negative predictive
value
PPV = positive predictive value
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1273H ighly sensitive troponin (hsTn) assays andcoronary computed tomography angiog-raphy (CTA) are promising candidates to
improve diagnostic accuracy in patients undergoing
evaluation for suspected acute coronary syndrome
(ACS) in the emergency department (ED) (1–7).Multiple
studies have shown that hsTn assays have increased
sensitivity for the detection of ACS and decreased
time to assay positivity compared to conventional
troponin (1–4). These assay characteristics suggest a
potential for faster andmore efﬁcient evaluation of pa-
tients presenting to the ED with symptoms suggestive
of ACS. Several recent studies suggested that even a
single very low measurement of hsTn at the time of
ED presentation can rule out myocardial infarction
(MI) safely (8–10). Further, increasing levels of hsTn
are associated with coronary artery disease (CAD) and
myocardial perfusion defects, and have prognostic
value beyond the acute care episode (11,12).SEE PAGE 1282Three large randomized trials have shown that
coronary CTA as compared to standard of care,
including serial conventional troponin and functional
testing to provoke myocardial ischemia, decreased
the time to diagnosis and allowed for earlier
discharge from the ED (5–7). Recent data suggest that
detection of high-risk coronary plaque features
(deﬁned as positive remodeling, low <30 Hounsﬁeld
units [HU] plaque, napkin-ring sign, or spotty cal-
cium) is independent and incremental to signiﬁcant
coronary stenosis for diagnosis of ACS (13). The
exclusion of high-risk plaque may help to decrease
downstream testing (e.g., additional stress testingMedical College, New York, New York; yyDivision of Cardiology and t
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crease in downstream testing was observed in
studies using the traditional assessment of
coronary CTA for stenosis (14–16).
Hence, there are expectations that a com-
bination of advanced coronary CTA with hsTn
may increase accuracy in the management of
patients presenting to the ED with suspected
ACS. We designed an observational cohort
study nested in the ROMICAT II (Rule Out
Myocardial Infarction/Ischemia using Com-
puter Assisted Tomography) trial. We deter-
mined whether combined assessment of
hsTnI and advanced coronary CTA for high-
risk plaque improves accuracy of ACS risk
classiﬁcation as compared to conventional
troponins and traditional coronary CTA
assessment for stenosis.METHODS
PATIENT POPULATION. The ROMICAT II trial ran-
domized patients presenting to the ED with sugges-
tive ACS but without ischemic electrocardiographic
changes and with negative conventional troponins
(see Online Table 1 for the conventional troponin
assays used in the study) (7). This ancillary study was
designed as a nested observational cohort study in
patients who were randomized to coronary CTA and
consented to blood sampling for hsTnI at the time of
ED presentation (Figure 1). All study participants
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FIGURE 1 Study Population Enrollment, Exclusion, and Inclusion
ROMICAT II  Coronary CTA 
     Arm (n = 501)
ROMICAT II Trial
(n = 1,000)
Study Population
(n = 160)
Patients With Coronary CTA
(n = 472)
Excluded:
- 28 Patients Not Undergoing Coronary CTA
- 1 Patient Due to Non-diagnostic Image Quality
Excluded:
- 499 Patients in Standard of Care Arm
Excluded:
- 312 Patients Without hsTn I Measurements
CONSORT diagram shows the inclusion and exclusion of patients resulting in the ﬁnal study
population of 160 patients. CONSORT ¼ consolidated standards of reporting trials; CTA ¼
computed tomography angiography; hsTn ¼ highly sensitive troponin; ROMICAT ¼ Rule
Out Myocardial Infarction/Ischemia using Computer Assisted Tomography.
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exclusion criteria, was reported previously (7).
BLOOD SAMPLES AND hsTnI TESTING. Blood was
collected into tubes containing ethylenedia-
minetetraacetic acid at baseline and immediately
processed and frozen at –80 centigrade until the
completion of the study. The samples were obtained
at the time of presentation. A second sample was
obtained at 90 to 115 min in 140 patients and a third
sample was obtained at 210 to 300 min in 105 pa-
tients. The blood was then analyzed in a blinded
fashion using a pre-clinical highly sensitive method
for detecting troponin I (hsVista, Siemens Diagnos-
tics, Newark, Delaware) (1). The limit of detection
and 99th percentile values for hsTnI were 0.5 pg/ml
and 49 pg/ml, respectively (17). We categorized pa-
tients into 3 groups: below the limit of detection
(LOD) for the assay (below LOD group), between the
LOD and the 99th percentile (intermediate group),
and above the 99th percentile (>99th percentile
group).CORONARY CTA ANALYSIS. Coronary CTA images
were acquired using 64-row or newer scanner gener-
ations using either retrospectively electrocardiogram-
gated or prospectively electrocardiogram-triggered
protocols (7). Three readers with at least 5 years of
experience in coronary CTA and level III training
performed the analysis on a dedicated cardiac work-
station (TeraRecon, Foster City, California). The cor-
onary CTA analysis was performed on a per coronary
segment basis using the model of the Society of
Cardiovascular Computed Tomography (18).
The traditional assessment of coronary CTA was
performed in all evaluable coronary segments. Each
segment was assessed for the presence of coronary
stenosis and plaque. The severity of stenosis was
categorized as: 0% ¼ no stenosis, 1% to 49% ¼ non-
obstructive CAD, $50% ¼ signiﬁcant CAD.
The advanced assessment for high-risk coronary
plaque was performed in all coronary segments with
plaque. High-risk plaque was deﬁned as the presence
of at least one of the following features: positive
remodeling (remodeling index >1.1), presence of
plaque with low computed tomographic attenuation
of <30 HU plaque, napkin-ring sign, and spotty
calcium (Figure 2) (13).
DEFINITION AND ADJUDICATION OF ACS. The pri-
mary outcome was ACS during the index hospitaliza-
tion. ACS was deﬁned as acute MI or unstable angina
pectoris according to the American College of Cardi-
ology/American Heart Association Guidelines (19).
This endpoint was pre-deﬁned and adjudicated by an
external, independent clinical endpoints committee
(Online Appendix) (7). The measurements of conven-
tional cardiac troponin at each site were available for
adjudication (Online Table 1 summarizes cutoff values
for each site). The results of hsTnI and advanced cor-
onary CTA analysis were blinded to the investigators
performing the adjudication.
STATISTICAL METHODS. All statistical analyses were
performed using Stata 13.1 (StataCorp LP, College
Station, Texas). Continuous data are presented as
mean  SD or median (interquartile range), and cate-
gorical variables are presented as numbers and per-
centages. Comparisons between groups were
performed with the use of an independent sample
Student t test, Wilcoxon rank-sum, or analysis of
variance for continuous variables, and the Fisher exact
test for categorical variables. For sensitivity, speci-
ﬁcity, and positive and negative predictive values,
95% conﬁdence intervals (CIs) were calculated using
exact binomial conﬁdence intervals. For the tradi-
tional coronary CTA assessment, the test was consid-
ered positive if there was any$50% stenosis or plaque.
For the combined hsTnI and advanced coronary CTA
FIGURE 2 High-Risk Plaque Features as Detected by Coronary CTA
(A) Low CT attenuation <30 HU plaque (*) in the distal left main coronary artery.
(B) Cross-sectional view of the vessel with noncalciﬁed plaque demonstrating napkin ring
sign with the central low HU area next to the lumen (*) surrounded by a peripheral rim of
higher CT attenuation (arrowhead). (C) Cross-sectional view of a partially calciﬁed plaque
with a spotty calciﬁcation (arrowhead). (D) Noncalciﬁed plaque with positive remodeling
(arrowheads). CT ¼ computed tomography; CTA ¼ computed tomography angiography.
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1275assessment, the test was considered positive if at least
1 of the 3 factors was present: hsTnI result was above
the 99th percentile at the time of presentation, $50%
stenosis or high-risk plaque present on coronary CTA.
Areas under the receiver operating characteristics
curve (AUC) were compared using the DeLong algo-
rithm (20). The net reclassiﬁcation index was calcu-
lated using themethod described by Pencina et al. (21).
For all analyses, a 2-tailed p value <0.05 was required
to reject the null hypothesis.
RESULTS
PATIENT POPULATION. Of 501 patients randomized
to coronary CTA in the ROMICAT II trial, 472 under-
went coronary CTA and had diagnostic image quality.
Of those, 160 agreed to participate in blood collection
and were included in the nested observational cohort
study (Figure 1). The baseline characteristics of the
study population are summarized in Table 1. The
mean age was 52.7  7.6 years. ACS during the index
hospitalization was diagnosed in 19 (10.6%) patients
(MI, n ¼ 2; unstable angina pectoris, n ¼ 17). There
were no signiﬁcant differences in baseline demo-
graphics, risk factors, and outcomes between patients
who agreed to blood collection and the overall cohort
of patients randomized to coronary CTA in the
ROMICAT II trial (Online Table 2).
CONVENTIONAL TROPONIN AND TRADITIONAL
CORONARY CTA AND ACS. By the ROMICAT II pro-
tocol, conventional troponin at the time of presenta-
tion to the ED was normal. Based on traditional
coronary CTA assessment, 42.5% of patients (n ¼ 68 of
160) had no CAD, 43.8% (n ¼ 70 of 160) had non-
obstructive CAD, and 13.8% (n ¼ 22 of 160) had signif-
icant CAD (Table 2). Reﬂecting clinical practice,
patients with normal conventional troponin at the
time of presentation and no CAD on coronary CTAwere
stratiﬁed as low risk (ACS rate: 0%) and patients who
had $50% stenosis on coronary CTA were stratiﬁed as
high risk for ACS (ACS rate: 72.7%). However, nearly
one-half of the patients remained at intermediate risk
having nonobstructive CAD (ACS rate: 4.3%) (Figure 3).
ASSOCIATION OF hsTnI AND ACS. In contrast to con-
ventional troponins, hsTnI permitted immediate-risk
stratiﬁcation at the time of ED presentation. Overall,
9 patients (5.6%) had hsTnI below the LOD and 12
(7.5%) had hsTnI above the 99th percentile. The
majority of patients had intermediate hsTnI levels
(n ¼ 139, 86.9%) (Table 1). The prevalence of ACS was
0% (n ¼ 0 of 9) when hsTnI was below the LOD, 8.6%
(n ¼ 12 of 139) in the intermediate hsTnI group and
58.3% (n ¼ 7 of 12) in patients with hsTnI above the
99th percentile. All events in the intermediate groupwere adjudicated as unstable angina pectoris. Hence,
using hsTnI, ACS could be ruled out safely in a small
group of patients, obviating the need for subsequent
coronary CTA.
The addition of the second and third hsTnI level
check did not allow for improvement of risk stratiﬁ-
cation (data not shown).
ASSOCIATION OF HIGH-RISK PLAQUE AND ACS. At
least 1 high-risk plaque feature was present in all
patients with ACS. Conversely, only 30.7% of patients
without ACS had high-risk plaque. The prevalence of
ACS in the coronary CTA strata of no high-risk
plaque and no $50% stenosis, either high-risk pla-
que or $50% stenosis, and both high-risk plaque
and $50% stenosis was 0.0%, 7.7%, and 69.2%,
respectively. Among patients with hsTnI above the
99th percentile, 66.7% of patients had $50% stenosis
and 88.3% of patients had high-risk plaque.
ASSOCIATION OF CAD AND HIGH-RISK PLAQUE
WITH hsTnI. Association between the hsTnI strata and
presence, extent, and composition of CAD are shown in
Table 2. Signiﬁcant associations were observed for all
high-risk plaque features and for signiﬁcant CAD
($50% stenosis) (p < 0.01 for each parameter), but not
for nonobstructive CAD, indicating that further
TABLE 1 Baseline Patient Characteristics
Total
(n ¼ 160)
hsTnI Below the
Limit of Detection
(n ¼ 9)
hsTnI Intermediate
(n ¼ 139)
hsTnI Above the
99th Percentile
(n ¼ 12) p Value
Mean age, yrs 52.7  7.6 47.4  5.7 53.0  7.5 53.8  8.7 0.091
Female 64 (40.0) 7 (77.8) 56 (40.3) 1 (8.3) 0.004
Cardiovascular risk factors
Hypertension 83 (51.9) 1 (11.1) 74 (53.2) 8 (66.7) 0.024
Diabetes mellitus 21 (13.1) 0 (0) 20 (14.4) 1 (8.3) 0.752
Dyslipidemia 71 (44.4) 2 (22.2) 63 (45.3) 6 (50.0) 0.409
Former or current smoker 85 (53.1) 6 (66.7) 71 (51.1) 8 (66.7) 0.434
Family history of premature CAD 50 (31.3) 3 (33.3) 43 (30.9) 4 (33.3) 1.000
Acute coronary syndrome
Myocardial infarction 2 (1.3) 0 (0) 0 (0) 2 (16.7) 0.008
Unstable angina pectoris 17 (10.6) 0 (0) 12 (8.6) 5 (41.7) 0.007
Values are mean  SD or n (%).
CAD ¼ coronary artery disease; hsTn ¼ highly-sensitive troponin.
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1276characterization of nonobstructive CAD for high-risk
plaque features is meaningful. None of the patients
with hsTnI below the LOD had $50% stenosis or high-
risk plaque on coronary CTA, whereas 33.3% of pa-
tients had nonobstructive CAD.
CAD CHARACTERISTICS AND hsTnI LEVELS IN
PATIENTS WITH INTERMEDIATED hsTnI. In a sub-
analysis, we compared CAD characteristics and hsTnI
levels in patients with intermediated levels of hsTn
(Table 3). Patients with ACS had higher prevalence
of $50% stenosis and high-risk plaque. The levels of
hsTnI were not different between those with and
without ACS.
COMPARISON OF THE DIAGNOSTIC ACCURACY OF
CONVENTIONAL TROPONIN AND TRADITIONAL
CORONARY CTA VERSUS hsTnI AND ADVANCED
CORONARY CTA. A ﬁrst hsTnI at the time of pre-
sentation followed by early coronary CTA withTABLE 2 Coronary CTA Characteristics of CAD and High-Risk Coronar
Total
(n ¼ 160)
hsTnI Be
Limit of D
(n ¼
Traditional CAD assessment (% stenosis)
No CAD (0) 68 (42.5) 6 (6
Nonobstructive CAD (1-49) 70 (43.8) 3 (3
Signiﬁcant CAD ($50) 22 (13.8) 0 (0
Advanced assessment of coronary CTA (%)
Any high-risk plaque 61 (38.1) 0 (0
Positive remodeling 26 (16.3) 0 (0
Low <30 HU plaque 20 (12.5) 0 (0
Napkin-ring sign 14 (8.8) 0 (0
Spotty calcium 56 (35.0) 0 (0
Values are n (%).
CTA ¼ computed tomography angiography; HU ¼ Hounsﬁeld units; other abbreviatioadvanced assessment for high-risk plaque improved
the accuracy of risk stratiﬁcation as compared to
conventional troponin level and traditional CTA
assessment (Figure 4).
Based on the ﬁrst hsTnI, coronary CTA would not be
needed in 13.1% of patients (n ¼ 21): 9 patients (5.6%)
with hsTnI below the LOD (ACS rate: 0%) and 12 pa-
tients (7.5%)with hsTnI above the 99th percentile (ACS
rate: 58.3%). In the remaining 139 patients with inter-
mediate hsTnI, the absence of both high-risk plaque
and $50% stenosis on coronary CTA excluded ACS in
87 patients (noCAD in 60 patients, nonobstructive CAD
in 27 patients). Among the remaining 52 patients, those
with either high-risk plaque or $50% stenosis repre-
sented an intermediate-risk group (n ¼ 39; ACS rate:
7.7%), and those who had both high-risk plaque
and $50% stenosis (n ¼ 13; ACS rate: 69.2%) repre-
sented a high-risk group. Hence, coronary CTA allowed
for reclassiﬁcation of the majority (72%, n ¼ 100 of 139)y Plaque Stratiﬁed by the Levels of hsTnI
low the
etection
9)
hsTnI Intermediate
(n ¼ 139)
hsTnI Above the
99th Percentile
(n ¼ 12) p Value
6.7) 60 (43.2) 2 (16.7) 0.066
3.3) 65 (46.5) 2 (16.7) 0.106
.0) 14 (10.1) 8 (66.7) <0.001
.0) 51 (36.7) 10 (83.3) <0.001
.0) 20 (14.4) 6 (50.0) 0.006
.0) 15 (10.8) 5 (41.7) 0.010
.0) 10 (7.2) 4 (33.3) 0.022
.0) 46 (33.1) 10 (83.3) <0.001
ns as in Table 1.
TABLE 3 Coronary CTA Characteristics and hsTnI Levels of Patients With Intermediate
hsTnI Stratiﬁed According to the Diagnosis of Acute Coronary Syndrome
Total
(n ¼ 139)
No ACS
(n ¼ 127)
ACS
(n ¼ 12) p Value
Traditional CAD assessment (% stenosis)
No CAD (0) 60 (43.2) 60 (47.2) 0 (0.0) 0.001
Non-obstructive CAD (1-49) 65 (46.8) 62 (48.8) 3 (25.0) 0.139
Signiﬁcant CAD ($50) 14 (10.1) 5 (3.9) 9 (75.0) <0.001
Advanced assessment of coronary CTA (%)
Any high-risk plaque 51 (36.7) 39 (30.7) 12 (100.0) <0.001
Positive remodeling 20 (14.4) 11 (8.7) 9 (75.0) <0.001
Low <30 HU plaque 15 (10.8) 9 (7.1) 6 (50.0) <0.001
Napkin-ring sign 10 (7.2) 5 (3.9) 5 (41.7) <0.001
Spotty calcium 46 (33.1) 34 (26.8) 12 (100.0) <0.001
hsTnI (pg/ml) 2.4 (1.3-4.7) 2.3 (1.4-4.6) 3.5 (1.1-6.1) 0.696
Values are n (%) or median (interquartile range).
ACS ¼ acute coronary syndrome; other abbreviations as in Tables 1 and 2.
FIGURE 3 Traditional Coronary CTA Assessment and ACS in the ROMICAT II Trial
Acute Chest Pain Patients 
(n = 160)
ACS = 19 (11.9%)
Cardiac Troponin and Electrocardiogram Negative at
the Time of Presentation to the Emergency Department
Coronary Plaque Present, Coronary Plaque andNo Coronary
Artery Disease
Coronary CTA
ACS Risk Based
On Traditional
Coronary CTA
Assessment
Intermediate Risk
(n = 70, 43.8%)
ACS = 3 (4.3%)
Low Risk
(n = 68, 42.5%)
ACS = 0 (0%)
High Risk
(n = 22, 13.8%)
ACS = 16 (72.7%)
Flow diagram depicts the risk stratiﬁcation based on the conventional troponin followed by the traditional assessment of coronary CTA for the
presence of coronary atherosclerotic plaque and $50% stenosis. ACS ¼ acute coronary syndrome; other abbreviations as in Figure 1.
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1277of patients in the intermediate hsTnI group for ACS risk
(Table 4). In 19 patients with ACS, 9 patients were
upgraded to high risk for ACS, and no patient was
downgraded to low risk for ACS when using advanced
coronary CTA results for reclassiﬁcation. The net gain
in reclassiﬁcation proportion for patients with ACSwas
0.47 (95% conﬁdence interval [CI]: 0.16 to 0.78; p ¼
0.003). The net gain in reclassiﬁcation proportion for
subjects who did not have ACS was 0.59 (95% CI: 0.46
to 0.72; p < 0.001); 87 of 141 patients were reclassiﬁed
downward and 4 of 141 were reclassiﬁed upward. The
net reclassiﬁcation index was thus calculated at 1.06
(95% CI: 0.73 to 1.40; p < 0.001).
The strategy of combined hsTnI and coronary CTA
with assessment for high-risk plaque as compared to
conventional troponin combined with traditional
coronary CTA increased the number of patients in
whom ACS could be ruled out from 68 (42.5%) to 96
(60.0%) and the number of patients at high risk for
ACS from 22 (13.8%) to 25 (15.7%), whereas the group
at intermediate risk decreased from 70 (43.8%) to 39
(24.4%) patients. Overall, the additional information
provided by hsTnI and high-risk plaque increased the
number of patients categorized into low- or high-risk
categories from 82 (51.3%) to 121 (75.6%).
The sensitivity and negative predictive value
of combined hsTnI and advanced coronary CTAassessment for ACS were maintained at 100% (similar
to conventional troponin and traditional coronary
CTA assessment) whereas the speciﬁcity improved
from 48.2% to 68.1% (Table 5). The combined
assessment of hsTnI and advanced coronary CTA for
high-risk plaque (AUC: 0.84, 95% CI: 0.80 to 0.88)
signiﬁcantly improved the diagnostic performance for
ACS as compared to traditional coronary CTA (AUC:
0.74, 95% CI: 0.70 to 0.78; p < 0.001).
TABLE 4
Presentat
High-Risk
Risk of AC
Tim
Low
Intermedia
High
Total
Abbreviatio
FIGURE 4 Combined hsTnI and Advanced Coronary CTA Assessment and ACS in the ROMICAT II Trial
Acute Chest Pain Patients
(n = 160)
ACS = 19 (11.9%)
No High-risk Plaque
and No Stenosis  50%
n = 87; ACS = 0 (0%)
High-risk Plaque
or Stenosis  50%
n = 52; ACS = 12 (23.1%)
Either High-risk Plaque
or Stenosis  50%
n = 39; ACS = 3 (7.7%)
Both High-risk Plaque
and Stenosis  50%
n = 13; ACS = 9 (69.2%)
Low Risk
(n = 96, 60%)
ACS = 0 (0%)
Intermediate Risk
(n = 39, 24.4%)
ACS = 3 (7.7%)
High Risk
(n = 25, 15.7%)
ACS = 16 (64.0%)
hsTn I Measured at
the Time of Presentation
Risk of ACS
According
to hsTn I
Low Risk
hsTn I < Limit of Detection
(n = 9, 5.6%)
ACS = 0 (0%)
Intermediate Risk
hsTn I Intermediate
(n = 139, 86.9%)
ACS = 12 (8.6%)
High Risk
hsTn I > 99th Percentile
(n = 12, 7.5%)
ACS = 7 (58.3%)
Coronary CTA
Re-classification of
ACS Risk After
Adding Coronary
CTA Characteristics
Flow diagram depicts the improvement of acute coronary syndrome (ACS) risk stratiﬁcation using hsTnI at the time of ED presentation. Further
improvement of the risk stratiﬁcation can be achieved with advanced assessment of coronary CTA for high-risk plaque. ED ¼ emergency
department; other abbreviations as in Figure 1.
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1278DISCUSSION
We showed that hsTnI at the time of the ED presenta-
tion followed by early coronary CTA with assessment
for stenosis and high-risk plaque improved the diag-
nostic accuracy for ACS in patients with suspected ACS
as compared to conventional troponin and traditional
coronary CTA assessment. This was based on: 1) the
ability of the ﬁrst hsTnI at the time of presentation to
stratify 13.1% into high- or low-risk ACS groups; 2) theReclassiﬁcation of ACS Risk Based on hsTnI at the Time of
ion Followed by Advanced Coronary CTA Assessment Including
Plaque
S Based on hsTnI at the
e of Presentation
Reclassiﬁcation of ACS Risk
by Advanced Coronary CTA
Assessment
TotalLow Intermediate High
9 0 0 9
te 87 39 13 139
0 0 12 12
96 39 25 160
ns as in Tables 2 and 3.reclassiﬁcation of 71.9% of those with intermediate
hsTnI by using additional information from the coro-
nary CTA assessment, thereby decreasing the fraction
of patients remaining at intermediate risk for ACS from
43.8% to 24.4%; and 3) the improvement in speciﬁcity
for ACS in those with intermediate hsTnI levels
through assessment of high-risk plaque (from 48.2% to
68.1%) while sensitivity and negative predictive value
for ACS were maintained at 100%. Overall, hsTnI at the
time of ED presentation followed by early coronary
CTA with assessment for stenosis and high-risk plaque
signiﬁcantly improved discriminatory ability for ACS
(AUC: 0.74 to 0.84; p < 0.001).
hsTn ASSAYS IN THE ASSESSMENT OF PATIENTS
WITH ACUTE CHEST PAIN. hsTn assays increase the
sensitivity for the detection of smaller amounts of
myocardial injury and also decrease the time to assay
positivity (1–4). There is growing evidence that hsTn
below the LOD measured at the time of presentation
has a negative predictive value of >99% for MI,
suggesting that it could serve as an early triage tool
(1–4,8–10). The triage effectiveness of hsTn using the
LOD threshold can be affected by the prevalence of
TABLE 5 Diagnostic Accuracy for ACS of Conventional Troponin and Traditional Coronary
CTA Assessment Versus hsTnI and Advanced Coronary CTA
Sensitivity Speciﬁcity PPV NPV AUC
Conventional troponin and
traditional CTA
100.0
(82.4-100.0)
48.2
(39.7-56.8)
20.7
(12.9-30.4)
100.0
(94.7-100.0)
0.74
(0.70-0.78)
hsTnI and advanced CTA 100.0
(82.4-100.0)
68.1
(59.7-75.7)
29.7
(18.9-42.4)
100.0
(96.2-100.0)
0.84
(0.80-0.88)
Values are % (95% conﬁdence interval).
AUC ¼ area under the receiver operating characteristics curve; NPV ¼ negative predictive value; PPV ¼ positive
predictive value; other abbreviations as in Tables 1, 2, and 4.
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1279hsTn below the LOD in a population. Prior studies
suggest that between 10% and 15% of patients with
suspected ACS have hsTnI below the LOD (1–4,10). We
found a slightly lower fraction of 6%, which likely
represents the extremely high analytical sensitivity of
this pre-commercial hsTnI method. None of the pa-
tients with hsTnI below the LOD had MI or unstable
angina pectoris suggesting that these patients do
not need to undergo coronary CTA and a direct
discharge from the ED can be considered. Although
among a small number of subjects, the importance of
this ﬁnding cannot be underestimated. Further
improvement in efﬁciency of ACS diagnosis may be
possible by combining hsTn and clinical risk assess-
ment, and by measuring short-term dynamic
changes of hsTn (8–10,22). This may lead to further
decreases in the numbers of patients requiring addi-
tional testing, including imaging. In addition, reduced
need for coronary CTA imaging can be achieved in
patients with hsTnI above the 99th percentile at the
time of presentation who are at high risk for ACS.
However, the major diagnostic challenge is the
large group of patients with intermediate levels of
hsTn. In a recent study, these patients had non-
negligible rates of ACS (8.3%) during the index hos-
pitalization and also signiﬁcantly higher rate of MI in
the ﬁrst 30 days after ED discharge versus patients
with hsTn T below the LOD (3.08% vs. 0.17%) (23).
Our results conﬁrm these observations (ACS rate:
8.6%) and suggest that patients with intermediate
hsTnI at the time of presentation require further
evaluation and cannot be safely discharged home.
Serial measurements of hsTnI improved the
detection and exclusion of ACS in previous studies
(22,24). In our study, the addition of second and third
hsTnI measurements at approximately 2 and 4 h after
the presentations did not improve ACS risk classiﬁ-
cation. However, serial hsTn measurements were not
available in all patients, potentially including bias to
our observations. Further studies will be needed to
explore whether serial hsTn measurements can help
in the management of patients, especially in patients
with CAD and intermediate stenosis on coronary CTA.
INCREMENTAL VALUE OF ADVANCED CORONARY
CTA ASSESSMENT. We showed the incremental value
of coronary CTA to accurately stratify patients with
intermediate hsTnI who are at intermediate risk of
ACS. We reclassiﬁed 71.9% of patients with interme-
diate hsTnI using coronary CTA and decreased the
fraction of patients remaining at intermediate risk for
ACS after both assessments from 43.8% to 24.4%.
This also improved speciﬁcity for ACS from 48.2% to
68.1% as compared to traditional coronary CTA and
was achieved because the presence of high-riskplaque and $50% stenosis carried a very high risk of
ACS (9 of 13 patients) in the group with intermediate
hsTnI. We showed that patients with nonobstructive
CAD, but no high-risk plaque did not develop ACS and
hence, the fraction of low-risk patients increased
from 42.5% to 60.0%, while maintaining sensitivity
and negative predictive values for ACS at 100%. These
ﬁndings resulted in a signiﬁcant improvement in
the discriminatory ability for ACS (AUC: 0.74 to 0.84;
p > 0.001).
The patients with intermediate hsTnI and either
high-risk plaque or $50% stenosis remained at in-
termediate risk of ACS (n ¼ 3 of 39). All 3 patients with
ACS had high-risk plaque, but none had $50%
stenosis. These ﬁndings are consistent with invasive
angiographic studies showing a minority of patients
(12% to 14%) who develop ACS in the absence of
hemodynamically signiﬁcant stenosis (25,26).
IMPLICATIONS FOR MANAGEMENT OF ACUTE
CHEST PAIN PATIENTS. Although this is an observa-
tional study, the results carry important implications
for patient management. We found a small but
important number of patients with hsTnI below the
LOD at the time of ED might be rapidly triaged home
without further testing. Further studies are war-
ranted to determine whether the fraction of patients
to be potentially immediately discharged without
coronary CTA can be improved by including risk fac-
tors and clinical characteristics of chest pain and
whether this fraction is stable across different hsTn
assays. After coronary CTA, 60% of patients,
including those with hsTnI below the LOD and those
with intermediated hsTnI, but no $50% coronary
stenosis and no high-risk plaque on coronary CTA,
could be candidates for immediate discharge. Pa-
tients with hsTnI above the 99th percentile at the
time of presentation are at high risk for ACS and
appropriate guideline recommended therapies, such
as dual antiplatelet therapy, high-dose statin, anti-
coagulation, and early invasive strategy could be
considered without coronary CTA. Similar guideline-
directed ACS therapies could be considered after
PERSPECTIVES
COMPETENCY IN PATIENT CAREAND PROCEDURAL
SKILLS: Our results provide new insights into the
accuracy of a management strategy for patients
presenting to the ED with suspected ACS. Combined
hsTnI at the time of presentation followed by early
coronary CTA with the assessment for both stenosis
and high-risk plaque improved the diagnostic accu-
racy for ACS as compared to conventional troponin
and traditional assessment of coronary CTA for ste-
nosis. The education of referring providers will be
critical to assure that the results of hsTn and
advanced coronary CTA are appropriately interpreted
and incorporated in the clinical decision making.
TRANSLATIONAL OUTLOOK: This was an obser-
vational study and no actual clinical decisions were
made based on the results of hsTnI and advanced
coronary CTA assessment. The use of combined hsTnI
and advanced assessment of coronary CTA should be
tested in a clinical trial in which clinical decisions and
care will be guided by the test results.
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1280coronary CTA shows both coronary stenosis and high-
risk plaque in patients with intermediate hsTnI as
they have a high risk of ACS. After the ﬁrst hsTnI and
early coronary CTA, approximately one-quarter of
patients remain at intermediate risk for ACS for
whom observation could be considered, including
serial troponin measurements, aspirin, statin, and a
stress test.
STUDY LIMITATIONS. The measurements of hsTnI
were available only in a subpopulation of patients
in the ROMICAT II trial. This limited our sample
size and could introduce a bias. However, the
baseline characteristics of patients with hsTnI
measurements were not signiﬁcantly different from
the entire population of patients in the coronary
CTA arm of the ROMICAT II trial. We only used 1
hsTn assay. The LOD, sensitivity, and speciﬁcity of
hsTn assays vary and thus could affect the perfor-
mance of the test. Our results might not be gener-
alizable to other hsTn assays. The strategy of hsTnI
at the time of presentation with early coronary CTA
was not pre-deﬁned in the ROMICAT II trial and no
actual ED disposition decisions were made based on
these results. As such, our data should be inter-
preted with caution and are mostly hypothesis
generating. The interpretation of coronary CTA im-
ages was performed in the setting of a core lab, by
experienced readers, and with unlimited time for
interpretation. Further prospective investigations
will be required to determine whether clinical cor-
onary CTA readers can reproduce the results and
whether coronary CTA assessment of high-risk pla-
que features can be implemented into clinical
workﬂow. Unstable angina pectoris is a clinical
diagnosis supported by more objective evidence on
advanced cardiac testing and remains a challenge
for clinicians and in the setting of clinical trials.
However, in the ROMICAT II trial, an independent
clinical endpoints committee provided a rigorous
high-quality adjudication of potential unstable
angina pectoris according to pre-deﬁned criteria.CONCLUSIONS
Combined hsTnI at the time of presentation followed
by early coronary CTA with the assessment for both
stenosis and high-risk plaque improved the diag-
nostic accuracy for ACS as compared to conventional
troponin and traditional assessment of coronary CTA.
This has the potential to improve risk stratiﬁcation of
ED patients presenting with symptoms suggestive of
ACS.
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